Use of phenytoin, phenobarbital, or diazepam during pregnancy and risk of congenital abnormalities: A case-time-control study

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 2, 2007, Pages 181-188

  Kjær, Dorte ^a   Horvath Puhó, Erzsébet ^c   Christensen, Jakob ^b,d   Vestergaard, Mogens ^a   Czeizel, Andrew E ^e   Sørensen, Henrik Toft ^d,f   Olsen, Jørn ^a,g  

^a UNIVERSITY OF AARHUS   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e FOUNDATION FOR THE COMMUNITY CONTROL OF HEREDITARY DISEASES   (Hungary)

^f BOSTON UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticonvulasants; Case time control study; Cognenital abnormalities; Diazepam adverse effects; Epidemiologic methods; Pharmacoepidemiology; Phenobarbital adverse effects; Phenytoin adverse effects; Pregnancy; Teratogens

Indexed keywords

CARBAMAZEPINE; DIAZEPAM; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ADULT; ANUS ATRESIA; ARTICLE; BONE MALFORMATION; CARDIOVASCULAR MALFORMATION; CLEFT LIP; CLEFT PALATE; CLINICAL TRIAL; CLUBFOOT; CONGENITAL HYDROCEPHALUS; CONGENITAL MALFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CRYPTORCHISM; DIAPHRAGM DISEASE; DRUG SURVEILLANCE PROGRAM; EAR MALFORMATION; EPILEPTIC STATE; ESOPHAGUS ATRESIA; ESOPHAGUS STENOSIS; FEMALE; FIRST TRIMESTER PREGNANCY; GASTROSCHISIS; GENITAL MALFORMATION; HUMAN; HYPOSPADIAS; INFANT; INTESTINE ATRESIA; INTESTINE STENOSIS; KIDNEY AGENESIS; LIMB DEFECT; MAJOR CLINICAL STUDY; MICROCEPHALY; MONOTHERAPY; NEURAL TUBE DEFECT; ORGANOGENESIS; PHARMACOEPIDEMIOLOGY; POPULATION BASED CASE CONTROL STUDY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEIZURE; SYNDACTYLY; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; UMBILICAL HERNIA; URINARY TRACT OBSTRUCTION;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTICONVULSANTS; CASE-CONTROL STUDIES; CROSS-OVER STUDIES; DIAZEPAM; FEMALE; HUMANS; HUNGARY; ODDS RATIO; PHENOBARBITAL; PHENYTOIN; POPULATION SURVEILLANCE; PREGNANCY; QUESTIONNAIRES; REGISTRIES; RISK ASSESSMENT; TIME FACTORS;

EID: 33847118008     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1288     Document Type: Article

References (44)

1. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001. 344 (15): 1132-1138.
2. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003. 60 (4): 575-579.
3. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999. 33(2-3): 145-158. DOI: 10.1016/ S0920-1211(98)00084-9
4. Matalon S, Schechtman S, Goldzweig G, et al. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 2002. 16 (1): 9-17. DOI: 10.1016/S0890-6238(01)0019-X
5. Sabers A, Dam M, Rogvi-Hansen B, et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004. 109 (1): 9-13. DOI: 10.1046/j.1600-0404.2003.00200.x">.
6. Samren EB, van Duijn CM, Christiaens GC, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999. 46 (5): 739-746.
7. Samren EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997. 38 (9): 981-990.
8. Fonager K, Larsen H, Pedersen L, et al. Birth outcomes in women exposed to anticonvulsant drugs. Acta Neurol Scand 2000. 101 (5): 289-294. DOI: 10.1034/j.1600-0404.2000.90193a.x
9. Wide K, Winbladh B, Källén B. Major malformations in infants exposed to antiepileptic drugs in utero with emphasis on carbamazepine and valporic acid: a nation-wide, population-based register study. Acta Paediatr 2004. 93: 174-176. DOI: 10.1080/08035250310021118
10. Olafsson E, Hallgrimsson JT, Hauser WA, et al. Pregnancies of women with epilepsy: a population-based study in Iceland. Epilepsia 1998. 39 (8): 887-892. DOI: 10.1111/j.1528-1157.1998.tb01186.x
11. Fairgrieve SD, Jackson M, Jonas P, et al. Population based, prospective study of the care of women with epilepsy in pregnancy. BMJ 2000. 321 (7262): 674-675. DOI: 10.1136/bmj.321.7262.674
12. Beghi E, Annegers JF. Pregnancy registries in epilepsy. Epilepsia 2001. 42 (11): 1422-1425. DOI: 10.1046/ j.1528-1157.2001.11201.x">1157.2001.11201.x
13. Cunnington MC. The international lamotrigine pregnancy registry update for the epilepsy foundation. Epilepsia 2004.45(11): 1468. DOI: 10.1111/ j.0013-9580.2004.451105.x
14. Russell AJ, Craig JJ, Morrison P, et al. U. K. Epilepsy and pregnancy group. Epilepsia 2004. 45(11): 1467. DOI: 10.1111/ j.0013-9580.2004.451104.x
15. Vajda F, Lander C, O'brien T, et al. Australian pregnancy registry of women taking antiepileptic drugs. Epilepsia 2004. 45 (11): 1466. DOI: 10.1111/j.0013-9580.2004.451103.x
16. Tomson T, Battino D, Bonizzoni E, et al. EURAP: An International Registry of Antiepileptic Drugs and Pregnancy. Epilepsia 2004. 45 (11): 1463-1464. DOI: 10.1111/j.0013-9580.2004.451101.x
17. Holmes LB, Wyszynski DF. North american antiepileptic drug pregnancy registry. Epilepsia 2004. 45 (11): 1465. DOI: 10.1111/ j.0013-9580.2004.451102.x
18. Rockenbauer M, Olsen J, Czeizel AE, et al. Recall bias in a case-control surveillance system on the use of medicine during pregnancy. Epidemiology 2001. 12 (4): 461-466.
19. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991. 133 (2): 144-153.
20. Suissa S. The case-time-control design. Epidemiology 1995. 6 (3): 248-253.
21. Greenland S. Confounding and exposure trends in case-crossover and case-time-control designs. Epidemiology 1996. 7 (3): 231-239.
22. Smith PE, Saunders J, Dawson A, et al. Intractable seizures in pregnancy. Lancet 1999. 354 (9189): 1522. DOI: 10.1016/ S0140-6736(99)09164-3
23. Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998. 339 (12): 792-798.
24. Czeizel AE, Rockenbauer M, Siffel C, et al. Description and mission evaluation of the Hungarian case-control surveillance of congenital abnormalities. 1980-1996. Teratology 2001. 63 (5): 176-185. DOI: 10.1002/ tera.1032
25. Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr 1975. 87 (2): 285-290.
26. Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000. 343 (22): 1608-1614.
27. Orup HI Jr, Holmes LB, Keith DA, et al. Craniofacial skeletal deviations following in utero exposure to the anticonvulsant phenytoin: monotherapy and polytherapy. Orthod Craniofac Res 2003. 6 (1): 2-19. DOI: 10.1046/ j.1439-0280.2003.2o212.x
28. Arpino C, Brescianini S, Robert E, et al. Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE). Epilepsia 2000. 41 (11): 1436-1443.
29. Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004. 61 (5): 673-678.
30. Dolovich LR, Addis A, Vaillancourt JM, et al. Benzodiazepine use in pregnancy and major malformations or oral cleft mete-analysis of cohort and case-control studies. BMJ 1998. 317 (7162): 839-843.
31. Meadow SR. Anticonvulsant drugs and congenital abnormalities. Lancet 1968. 2 (7581): 1296.
32. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation - a reference guide to fetal and neonatal risk (6th edn). Williams and Wilkins: Philadelphia, USA, 2002.
33. Rothman KJ, Fyler DC, Goldblatt A, et al. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol 1979. 109 (4): 433-439.
34. Saxen I. Associations between oral clefts and drugs taken during pregnancy. Int J Epidemiol 1975. 4 (1): 37-44.
35. Czeizel A, Eros E, Rockenbauer M, et al. Short-term oral diazepam treatment during pregnancy. A population-based temtological case-control study. Clin Drug Invest 2003. 23 (7): 451-462.
36. Khan KS, Wykes C, Gee H. Benzodiazepine use in pregnancy and major malformations or oral clefts. Quality of primary studies must influence inferences made from meta-analyses. BMJ 1999. 319 (7214): 919.
37. Cates C. Benzodiazepine use in pregnancy and major malformations or oral clefts. Pooled results are sensitive to zero transformation used. BMJ 1999. 319 (7214): 918-919.
38. Garne E, Bergman U. Benzodiazepine use in pregnancy and major malformations or oral clefts. Induced abortions should be included. BMJ 1999. 319 (7214): 918.
39. Czeizel A, Racz J. Evaluation of drug intake during pregnancy in the Hungarian case-control surveillance of congenital anomalies. Teratology 1990. 42 (5): 505-512.
40. Bergman U, Rosa FW, Baum C, et al. Effects of exposure to benzodiazepine during fetal life. Lancet 1992. 340 (8821): 694-696.
41. Moller J, Hessen-Soderman AC, Hallqvist J. Differential misclassification of exposure in case-crossover studies. Epidemiology 2004. 15 (5): 589-596. DOI: 10.1097/01.ede.0000135177.10332.42
42. Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health 2000. 21: 193-221. DOI: 10.1146/annurev.publhealth.21.1.193
43. Hernandez-Diaz S, Hernan MA, Meyer K, et al. Case-crossover and case-time-control designs in birth defects epidemiology. Am J Epidemiol 2003. 158 (4): 385-391. DOI: 10.1093/aje/kwg144
44. Meyer KA, Williams P, Hernandez-Diaz S, et al. Smoking and the risk of oral clefts: exploring the impact of study designs. Epidemiology 2004. 15 (6): 671-678. DOI: 10.1097/01.ede.0000142148.51230.60